NEW YORK, April 22 (GenomeWeb News) - An analyst at Robert W. Baird downgraded Affymetrix's stock this morning to "neutral" from "outperform," causing shares in the microarray company to fall 6 percent in early-morning trading.


The stock recovered some of the slide, trading down 2.46, or $1.13, at $44.88 in heavy volume in the mid-afternoon.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

360Dx reports that the US Centers for Medicare & Medicaid Services would cover next-generation sequencing-based cancer panel tests.

The Washington Post reports that a meteorologist is being considered as presidential science and technology advisor.

In PNAS this week: precision medicine strategy to screen for disease risk, genome evolution in Haemophilus influenzae, and more.

Researchers have developed a PCR-based assay to gauge whether manatees are present in waters.